Capricor Therapeutics, Inc. (CAPR) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $31.32 (-6.70%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | Kristen Kluska | Cantor Fitzgerald | $62.00 | +98.0% |
| Nov 11, 2025 | Boobalan Pachaiyappan | Roth Capital | $13.00 | -58.5% |
| Jul 11, 2025 | Edward Tenthoff | Piper Sandler | $20.00 | -36.1% |
| Jul 11, 2025 | Joseph Pantginis | H.C. Wainwright | $24.00 | -23.4% |
| Oct 21, 2024 | Edward Tenthoff | Piper Sandler | $17.50 | -44.1% |
| Oct 14, 2024 | Leland Gershall | Oppenheimer | $21.50 | -31.3% |
| Sep 25, 2024 | Jason McCarthy | Maxim Group | $12.50 | -60.1% |
| Sep 25, 2024 | Joseph Pantginis | H.C. Wainwright | $10.00 | -68.1% |
| Sep 17, 2024 | Leland Gershall | Oppenheimer | $7.50 | -76.0% |
| May 16, 2024 | Leland Gershall | Oppenheimer | $7.00 | -77.6% |
Top Analysts Covering CAPR
CAPR vs Sector & Market
| Metric | CAPR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 10 | 8 | 18 |
| Target Upside | +52.5% | +1150.2% | +14.9% |
| P/E Ratio | -15.80 | 6.88 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $2M | $2M | $2M | 1 |
| 2026-09-30 | $68M | $68M | $68M | 1 |
| 2026-12-31 | $89M | $89M | $89M | 2 |
| 2027-03-31 | $13M | $13M | $13M | 1 |
| 2027-06-30 | $19M | $19M | $19M | 2 |
| 2027-09-30 | $24M | $24M | $24M | 2 |
| 2027-12-31 | $44M | $44M | $44M | 1 |
| 2028-12-31 | $16M | $279M | $595M | 5 |
| 2029-12-31 | $26M | $449M | $958M | 2 |
| 2030-12-31 | $37M | $629M | $1.34B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.59 | $-0.52 | $-0.48 | 6 |
| 2026-09-30 | $0.39 | $0.39 | $0.39 | 3 |
| 2026-12-31 | $0.89 | $0.89 | $0.89 | 4 |
| 2027-03-31 | $-0.31 | $-0.31 | $-0.31 | 2 |
| 2027-06-30 | $-0.23 | $-0.23 | $-0.23 | 2 |
| 2027-09-30 | $-0.17 | $-0.17 | $-0.17 | 2 |
| 2027-12-31 | $0.14 | $0.14 | $0.14 | 2 |
| 2028-12-31 | $1.04 | $2.04 | $4.94 | 5 |
| 2029-12-31 | $-0.90 | $4.03 | $9.98 | 1 |
| 2030-12-31 | $-1.33 | $5.93 | $14.67 | 1 |
Frequently Asked Questions
What is the analyst consensus for CAPR?
The consensus among 10 analysts covering Capricor Therapeutics, Inc. (CAPR) is Buy with an average price target of $47.75.
What is the highest price target for CAPR?
The highest price target for CAPR is $62.00, set by Kristen Kluska at Cantor Fitzgerald on 2026-03-13.
What is the lowest price target for CAPR?
The lowest price target for CAPR is $7.00, set by Leland Gershall at Oppenheimer on 2024-05-16.
How many analysts cover CAPR?
10 analysts have issued ratings for Capricor Therapeutics, Inc. in the past 12 months.
Is CAPR a buy or sell right now?
Based on 10 analyst ratings, CAPR has a consensus rating of Buy (2.00/5) with a +52.5% upside to the consensus target of $47.75.
What are the earnings estimates for CAPR?
Analysts estimate CAPR will report EPS of $-0.52 for the period ending 2026-06-30, with revenue estimated at $2M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.